O Koren, V Patel, R Naami, E Naami, T Nagasaka… - researchgate.net
Objective: To assess the incidence of new adverse coronary events (NACE) following transcatheter aortic valve replacement (TAVR) and valve-in-valve TAVR (ViV-TAVR) …
O Koren, V Patel, R Naami, E Naami… - Frontiers in …, 2022 - ncbi.nlm.nih.gov
Objective To assess the incidence of new adverse coronary events (NACE) following transcatheter aortic valve replacement (TAVR) and valve-in-valve TAVR (ViV-TAVR) …
O Koren, V Patel, R Naami, E Naami… - Frontiers in …, 2022 - pubmed.ncbi.nlm.nih.gov
Objective To assess the incidence of new adverse coronary events (NACE) following transcatheter aortic valve replacement (TAVR) and valve-in-valve TAVR (ViV-TAVR) …
O Koren, V Patel, R Naami, E Naami, T Nagasaka… - academia.edu
Objective: To assess the incidence of new adverse coronary events (NACE) following transcatheter aortic valve replacement (TAVR) and valve-in-valve TAVR (ViV-TAVR) …
O Koren, V Patel, R Naami, E Naami… - Frontiers in …, 2022 - europepmc.org
Objective To assess the incidence of new adverse coronary events (NACE) following transcatheter aortic valve replacement (TAVR) and valve-in-valve TAVR (ViV-TAVR) …
O Koren, V Patel, R Naami, E Naami, T Nagasaka… - academia.edu
Objective: To assess the incidence of new adverse coronary events (NACE) following transcatheter aortic valve replacement (TAVR) and valve-in-valve TAVR (ViV-TAVR) …